For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: October 24-30, 2026
FDA and innovation FDA and CMS move on personalized gene therapies. The FDA released draft guidance that lets developers of…
Blog
Market-oriented reforms that can save Medicare $100 billion
Since 1970, Medicare spending has grown from 0.7 percent of GDP to 4.0 percent of GDP, and it is projected to grow even further.
Blog
This week in health care policy: October 16–23, 2026
Medical innovation FDA approves several innovative treatments. Last week, the FDA granted accelerated approval to GSK’s Jemperli for certain untreated…
Search Posts
Op-Eds
Drug Testing, Drug Hazards
A clinical trial that went badly awry at London's Northwick Park Hospital in March became the drug-testing community's worst nightmare. Six healthy volunteers ended up…
Blog
A typology for risk assessment?
New research may help to explain why the term “risk” shouldn’t automatically be applied to new technologies, such as biotechnology. According to…
Op-Eds
Lance Armstrong’s Self-Inflicted Cancer?
Did the use of performance-enhancing drugs cause seven-time Tour de France winner Lance Armstrong’s testicular cancer? That’s what a Sports Illustrated columnist suggested this…
Newsletter
The Competitive Enterprise Institute Daily Update
Issues in the News 1. HEALTH The Food and Drug Administration approves the first fully implantable artificial heart.
Newsletter
The Competitive Enterprise Institute Daily Update
Issues in the News 1. ENERGY President Bush makes access to affordable energy the focus of his Labor Day…
Op-Eds
Why spurning food biotech has become a liability
Henry I. Miller, MD, Gregory Conko & Drew L. Kershen By rejecting gene-spliced ingredients in their products, some major food companies may be…